Efbemalenograstim alfa is a granulocyte-colony stimulating factor used to treat prevent chemotherapy-induced neutropenia. As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim alfa can stimulate the production of neutrophils and thus reducing the severity and...
- Mechanism
- Curator reviewed · 1 reference
Efbemalenograstim alfa-vuxw is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end-cell functional activation.
- Primary indication
- Efbemalenograstim alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.Curator reviewed · 1 structured indication
- First approval
- United States, 2023 · European Union, 2024
- Also known as
- Benegrastim · Recombinant dimeric g-csf fusion protein f627 · Rh g-csf fc fusion protein f-627
- Code names
- F-627
- Brand names
Resolves to
What you can answer from here — as of September 05, 2026
Which drugs share a target with Efbemalenograstim alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account